Prothena

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Prothena reports robust earnings, advances Alzheimer's treatments with promising results

Prothena's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements in neurodegenerative diseases, and promising results in key programs like PRX012 and Birtamimab.
Challenges include navigating reimbursement changes, dosing complexities, and ensuring accelerated approval pathways for Alzheimer's treatments.
Opportunities lie in leveraging financial strength for pipeline expansion, upcoming data releases, innovative treatment approaches, and establishing leadership in niche disease areas.
Overall, Prothena's strategic focus on innovative therapies and deep understanding of disease mechanisms position the company for continued growth and clinical success.

Prothena reports robust financials and promising clinical advancements in Q4

Prothena's Q4 2023 earnings call highlighted strong financials, progress in key clinical programs, and promising results in movement disorder studies.
While facing challenges in patient enrollment and dose optimization, the company's focus on specialized therapies and patient-centric development positions it well for future growth.
Opportunities lie in optimizing dosing strategies, enhancing treatment efficacy, and leveraging exposure response data to drive innovation and improve therapeutic outcomes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Strength Seen in Prothena (PRTA): Can Its 7.3% Jump Turn into More Strength?

Prothena has developed broad expertise in removing plaques across different pathologies.

Prothena: Well-Positioned In Parkinson's And Alzheimer's

The stock price of Prothena Corporation (NASDAQ: PRTA), a biotechnology company focused on treatment of diseases that involve protein misfolding or cell adhesion, has seen a a large 13% drop over the last five trading days. The decline in PRTA stock came after another pharmaceuticals company.

Will Prothena Stock Rebound After A 13% Drop Last Week?

DUBLIN, Ireland, June 24, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that Bristol Myers Squibb exercised its option under the global neuroscience research and development collaboration to enter into an exclusive U.S. license for PRX005 and will pay Prothena $80 million. PRX005 is designed to be a best-in-class anti-tau antibody by specifically targeting an area within the microtubule binding region (MTBR) for the potential treatment of Alzheimer's disease (AD). Phase 1 study with PRX005 has initiated.

Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration

Prothena (PRTA) surges on the prospects of its Alzheimer's disease drug candidates, following Biogen???s AD drug approval.

Here's Why Prothena (PRTA) Stock Is Up So Far This Month

Biogen

Eli Lilly

The FDA's approval of Biogen's Aduhelm in treating Alzheimer's disease boosted all three stocks.

Why Biogen, Lilly, and Prothena Stocks Soared This Week

DUBLIN, Ireland, June 10, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the JMP Securities Life Sciences Conference on Wednesday, June 16 at 3:00 PM ET

Prothena to Participate in JMP Securities Life Sciences Conference on June 16

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

Prothena (PRTA) Up 78.2% Since Last Earnings Report: Can It Continue?

Annovis Bio

Arvinas Inc

Anavex Life Sciences

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Biohaven Pharmaceutical Hld

Loncar Cancer Immunotherapy ETF

Denali Therapeutics

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

abrdn Life Sciences Investors 

iShares Nasdaq Biotechnology ETF

Defiance Nasdaq Junior Biotechnology ETF

INmune Bio Inc

Intra-Cellular Therapies

Karuna Therapeutics Inc

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Invesco Dynamic Biotechnology & Genome ETF

Cassava Sciences Inc

Supernus Pharmaceuticals

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector.

Biotechs Ready To Roar

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Prothena (PRTA) Moves 5.9% Higher: Will This Strength Last?

Avadel Pharma

Neurocrine Biosciences

SAGE Therapeutics

Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.

Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment

DUBLIN, Ireland, May 20, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Sanjiv K. Patel, MBBS, MA, MBA, to its Board of Directors.

Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors

Prothena (PRTA) reports a wider loss in the first quarter of 2021. The pipeline remains in focus with the planned initiation of three late-stage studies for birtamimab, prasinezumab and PRX004.

Prothena (PRTA) Q1 Loss Wider Than Expected, Pipeline in Focus

DUBLIN, Ireland, May 11, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2021. In addition, the Company provided an update on its R&D programs and 2021 financial guidance.

Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update

Prothena Corporation plc (NASDAQ: PRTA) has dosed the first patient in the Phase 2b PADOVA study evaluating prasinezumab in patients with early Parkinson's disease. Prasinezumab is an anti-alpha synuclein antibody.

Prothena Receives $60M Milestone Payment After Parkinson's Candidate Moves Forward In Mid-Stage Study With Dosing

Catalyst Pharmaceuticals

Harmony Biosciences Holdings

Myovant Sciences

Let us take a look at four small companies, CPRX, MYOV, PRTA, HRMY, which are gearing up for their earnings release.

Drug/Biotech Stock Q1 Earnings on May 10: CPRX, PRTA & More

DUBLIN, Ireland, May 04, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, announced today that it will report its first quarter 2021 financial results on Tuesday, May 11, 2021 after the close of the U.S. financial markets.

Prothena to Report First Quarter 2021 Financial Results on May 11th

The stock price of Prothena Corporation, a biotechnology company focused on treatment of diseases that involve protein misfolding or cell adhesion, has seen a 9% rise over the last five trading days, after the company announced that PRX004 phase 1 study results were selected for Emerging Science.

What's Next For Prothena Stock After A 9% Rise This Week?

DUBLIN, Ireland, April 18, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) today presented positive results from the Phase 1 study of PRX004 as part of the Emerging Science Session at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting. PRX004 showed favorable results as demonstrated by slowing of neuropathy progression for all 7 evaluable patients at 9 months, including improvement in neuropathy in 3 of the 7 patients, and improved cardiac systolic function for all 7 patients. In this Phase 1 study, PRX004 was found to be generally safe and well tolerated across all dose levels. The positive results were presented by Dr. Ole Suhr, Senior Professor, Department of Public Health and Clinical Medicine, Umeå University, gastroenterologist and internist who was a principal investigator in the study and were previously highlighted by Prothena on December 9, 2020.

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021

3 Biotech Neurology Stocks Pursuing Alzheimer's And Parkinson's Diseases

DUBLIN, Ireland, April 15, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that results from its Phase 1 study of PRX004 in ATTR amyloidosis have been selected for an oral presentation as part of the Emerging Science Session on Sunday, April 18th at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting. The results will be presented by Dr. Ole Suhr, Senior Professor, Department of Public Health and Clinical Medicine, Umeå University, a gastroenterologist and internist who was a principal investigator in the study. The positive results from this study were previously highlighted by Prothena in December 2020.

Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021

Dr. Garren's extensive expertise and successful track record of advancing neurology and rare disease programs through late-stage development, registration and launch supports Company's transition to a fully-integrated R&D and commercial business Dr. Garren's extensive expertise and successful track record of advancing neurology and rare disease programs through late-stage development, registration and launch supports Company's transition to a fully-integrated R&D and commercial business

Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Prothena (PRTA) Stock Jumps 16.8%: Will It Continue to Soar?

DUBLIN, Ireland, March 24, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that it priced an underwritten public offering of 3,500,000 of its ordinary shares at a price to the public of $20.75 per ordinary share, before the underwriting discount and estimated offering expenses. All of the ordinary shares in the offering were sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 525,000 of its ordinary shares.

Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares

DUBLIN, Ireland, March 23, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that it has commenced an underwritten public offering of its ordinary shares. All of the ordinary shares in the offering will be sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold.

Prothena Announces Proposed Offering of Ordinary Shares

News for Prothena Stock (PRTA)